Our findings validate previous research showing that SEMA3C knockdown inhibits the proliferation of ER+ breast cancer cells, and extends these insights by demonstrating that SEMA3C is an autocrine growth factor that stimulates the growth of ER+ cell lines. Here, ESR1 is linked to breast cancer.